Sohini Das &Amp; Vinay Umarji

Stories by Sohini Das &Amp; Vinay Umarji

Covid: How Pfizer plans to resolve cold storage issues in India

Covid: How Pfizer plans to resolve cold storage issues in India

Rediff.com   7 Dec 2020

The company has developed detailed logistical plans and tools to support effective vaccine transport, storage, and temperature monitoring. Sohini Das and Ruchika Chitravanshi report.

At 1.39 crore, is this IITs' highest job offer this year?

At 1.39 crore, is this IITs' highest job offer this year?

Rediff.com   3 Dec 2020

The likes of Microsoft and Cohesity have offered crore plus salaries to some students.

IIT placements: Will Microsoft offer Rs 1.2 crore salary this year too?

IIT placements: Will Microsoft offer Rs 1.2 crore salary this year too?

Rediff.com   2 Dec 2020

IITs anticipate COVID-19 restrictions to impact international offers being extended by global recruiters.

How states are preparing for Covid vaccine distribution

How states are preparing for Covid vaccine distribution

Rediff.com   2 Dec 2020

Each state has its own weak areas that need attention. Some states have already identified the gaps and sought the Centre's help. Vinay Umarji, Ishita Ayan Dutt, Samreen Ahmad and Sohini Das report.

India may get first Covid-19 vaccine by February

India may get first Covid-19 vaccine by February

Rediff.com   30 Nov 2020

The government plans to immunise 30 million people in the first phase, starting February, and by July, the target is to vaccinate 250 million people, reports Sohini Das.

Indian Immunologicals to set up new vaccine plant, raise capacity by 35%

Indian Immunologicals to set up new vaccine plant, raise capacity by 35%

Rediff.com   26 Nov 2020

The company has a pipeline of viral vaccines including Zika, dengue, varicella, as well as a potential Covid-19 inoculation.

Serum Institute to keep 200 mn doses of Covid vaccine ready by Jan

Serum Institute to keep 200 mn doses of Covid vaccine ready by Jan

Rediff.com   13 Nov 2020

'SII has started stockpiling the vaccine and now has roughly 40 million doses ready. It is using some of the capacities it had for under development products for the COVID-19 vaccine and by January we will have a capacity to make 100 million doses per month and a stockpile of 200 million doses.'

Nearly 90% companies planning salary hikes in 2021

Nearly 90% companies planning salary hikes in 2021

Rediff.com   5 Nov 2020

Among the sectors, the survey has projected IT, pharma and life sciences, and ITeS among those looking to effect the highest increase in salaries.

Pandemic pushes up demand for CT scanners; firms gear up to meet surge

Pandemic pushes up demand for CT scanners; firms gear up to meet surge

Rediff.com   4 Nov 2020

Siemens Healthineers, one of the largest manufacturers of made-in-India CT scanners, has sold 80-100 such machines in the last 45 days. The medical technology firm typically sells 250 machines in a year.

Bharat Biotech starts Covaxin's at-risk manufacture

Bharat Biotech starts Covaxin's at-risk manufacture

Rediff.com   2 Nov 2020

The first vaccine candidate will be an intra-muscular one, followed by intra-dermal and nasal ones, depending on test results.

Why Dr Reddy's had to shut all its units

Why Dr Reddy's had to shut all its units

Rediff.com   25 Oct 2020

Security breach came days after the firm got approval to conduct trials for Covid-19 vaccine candidate Sputnik V.

Covid-19 impact: Low interest loans likely for vaccine companies

Covid-19 impact: Low interest loans likely for vaccine companies

Rediff.com   10 Oct 2020

While there has been no commitment from the government on the procurement of vaccines, initial volumes, or distribution plans, there is a likelihood that the low interest loans may be made available to these players only when the time to scale up manufacturing arises.

Wow! IITians bag international internships

Wow! IITians bag international internships

Rediff.com   6 Oct 2020

IIT-Delhi saw international training offers from Hong Kong, South Korea and the US.

Covaxin: How Bharat Biotech plans to boost immunity

Covaxin: How Bharat Biotech plans to boost immunity

Rediff.com   6 Oct 2020

Adjuvants may be added to a vaccine to produce more antibodies and longer lasting immunity thus minimising the dose of antigen needed.

Sales of Biocon's itolizumab surge as phase-4 clinical trials begin

Sales of Biocon's itolizumab surge as phase-4 clinical trials begin

Rediff.com   6 Oct 2020

In India, itolizumab, known by the brand name Alzumab, has been priced at Rs 8,000 per vial. Most patients require four vials for Covid-19 treatment, taking the cost of the therapy to Rs 32,000.

Covid vaccine: Pharma firms ready expansion plans

Covid vaccine: Pharma firms ready expansion plans

Rediff.com   6 Oct 2020

The Indian vaccine industry largely feels there are two ways in which vaccine innovation can be spurred - one, get a high price for the product and two, have the government buy a few hundred million doses of the product at a certain price.

How India is gearing up to distribute Covid-19 vaccine

How India is gearing up to distribute Covid-19 vaccine

Rediff.com   18 Sep 2020

A model being considered is to have a combined cold chain approach - where the agricultural cold chain would be combined with vaccine cold chains.

'Amul is India's biggest FMCG company'

'Amul is India's biggest FMCG company'

Rediff.com   17 Sep 2020

'We plan to touch Rs 1 trillion of Amul brand's turnover in the next five years.'

Labs bet on Covid tests for next growth phase

Labs bet on Covid tests for next growth phase

Rediff.com   14 Sep 2020

The bouquet of Covid-19 tests that most diagnostic labs are offering include antibody tests (blood tests), rapid antigen tests (point of care tests that detect the presence of an antigen from a nasal or throat swab in case of SARS-CoV-2), and reverse transcription-polymerase chain reaction (RT-PCR) tests.

India will wait for DCGI nod to restart Oxford vaccine trial

India will wait for DCGI nod to restart Oxford vaccine trial

Rediff.com   11 Sep 2020

The global trials were halted after a study participant suffered a 'potentially unexplained illness, reports Sohini Das.